Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 64 Neoplasm Metastasis 14 Brain Neoplasms 10 Neoplasms 9 Endometrial Neoplasms 8 Prostatic Neoplasms 7 Glioblastoma 7 Ovarian Neoplasms 6 Triple Negative Breast Neoplasms 5 Glioma 5 Sarcoma 3 Recurrence 3 Neoplasms by Site 3 Meningioma 3 Carcinoma, Non-Small-Cell Lung 3 Breast Diseases 3 Unilateral Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Osteosarcoma 2 Liposarcoma 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Ependymoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Renal Cell 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × abemaciclib × 1 year × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡